Introduction
============

Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder characterized by hyperactivity, impulsivity, and difficulty maintaining sustained attention.[@b1-ndt-10-1543] Approximately 5.3% of children and adolescents are affected by ADHD worldwide,[@b2-ndt-10-1543] of whom 60% continue to demonstrate notable ADHD symptoms throughout life.[@b3-ndt-10-1543]

Pharmacologic treatment is a key component of evidence-based care for patients with ADHD and has been shown to be a cost-effective therapeutic option.[@b4-ndt-10-1543] Currently, there are two main classes of medications with proven efficacy for ADHD -- stimulants and nonstimulants. Stimulants, such as amphetamines (AMPHs) and methylphenidates (MPHs), have been the mainstay of ADHD pharmacotherapy.[@b5-ndt-10-1543] For patients with contraindications, or those who are averse or nonresponsive to stimulants, nonstimulants, such as guanfacine extended release (GXR), atomoxetine (ATX), and clonidine hydrochloride extended release, are alternative treatment options.

Owing to the chronic nature of ADHD symptoms, patients with ADHD typically require long-term pharmacotherapy. Despite the demonstrated effectiveness of current ADHD medications, treatment discontinuation is fairly common. One-half of all patients fail to adhere to treatment guidelines[@b6-ndt-10-1543] or discontinue treatment within 2--3 years of starting pharmacologic therapy.[@b7-ndt-10-1543],[@b8-ndt-10-1543] Such behaviors may be associated with suboptimal control of ADHD symptoms,[@b9-ndt-10-1543] increasing the likelihood of serious deleterious effects that can accrue and escalate over time.[@b10-ndt-10-1543] These include social and academic difficulties, behavioral problems such as substance abuse, delinquency, accidental injury,[@b11-ndt-10-1543],[@b12-ndt-10-1543] and poor economic, social, and emotional well-being.[@b12-ndt-10-1543],[@b13-ndt-10-1543] Such consequences impact patients as well as their families and communities.

The decision to discontinue treatment can be associated with a variety of factors, including patient characteristics, patient or caregiver choice, medication-related factors (eg, duration of action, risk--benefit profile, etc), and practitioner-related or health system-related factors.[@b14-ndt-10-1543],[@b15-ndt-10-1543] Although the literature exists on reasons for ADHD treatment discontinuation, a comprehensive review of these studies synthesizing the underlying issues surrounding discontinuation (particularly for specific ADHD populations, medication classes, and geographic locations) could facilitate the design of programs to improve treatment adherence and subsequent patient health outcomes, and would benefit both researchers and providers. This study aimed to meet this need by conducting a systematic literature review of real-world observational studies and review articles of expert opinions on medication discontinuation among patients with ADHD. In particular, the study sought to accomplish three objectives: 1) to explore the extent of patient persistence on (or discontinuation of) ADHD treatment; 2) to examine patient adherence to various ADHD medications; and 3) to evaluate the underlying reasons for patients' treatment discontinuation. Variations of discontinuation rates, adherence, and reasons for treatment discontinuation were analyzed across subgroups of patients by age group, geographic location, and medication class.

Materials and methods
=====================

Systematic literature search
----------------------------

A systematic literature review was performed on October 11, 2013, by searching four main electronic databases via the OvidSP[@b16-ndt-10-1543] interface: MedLine[@b17-ndt-10-1543] (including In-Process and Other Non-Indexed Citations, January 1990--September 2013); EMBASE[@b18-ndt-10-1543] (January 1990--September 2013); PsycINFO[@b19-ndt-10-1543] (January 1990--September 2013); and Cochrane Database of Systematic Reviews[@b20-ndt-10-1543] (January 2005--July 2013). The four sets of search terms used were: disease of interest (terms for "attention- deficit hyperactivity disorder"); selected medication treatments (terms listed in [Table S1](#SD1-ndt-10-1543){ref-type="supplementary-material"}); treatment discontinuation (terms for discontinuation, adherence, or persistence); and eligible study types (terms for retrospective or observational studies). Publications retrieved from the search were screened using the inclusion and exclusion criteria detailed in [Table 1](#t1-ndt-10-1543){ref-type="table"}, and this review followed the reporting guidelines recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).[@b21-ndt-10-1543]

Publications were screened at two levels. At the level I screening, inclusion/exclusion criteria were applied at the title/abstract level. At the level II screening, the full text of each article was reviewed against the selection criteria. The reason for its exclusion was recorded for each article failing level I or level II screening. To ensure complete capture of all relevant studies, the bibliographies of all reviews and meta-analysis articles were examined during level II screening to identify any additional original studies previously not included (via the snowballing technique).[@b22-ndt-10-1543] Reviews and meta-analyses were included for data extraction if they reported expert opinions and/or were not based on original studies. Two researchers conducted the level I and level II screenings independently; a third researcher was consulted to arbitrate disagreements over study inclusions when needed.

Multiple publications (kin studies) arising from the same research study (primary publications) were identified based on the study sample, research team, analytical method, and results, and linked to avoid duplication. Information was extracted from the primary study and, if available, additional information from the kin studies was also extracted and combined with the primary study. Because we sought to understand the nature of all of the available literature on these topics, the scientific quality of the published studies was not assessed in this systematic literature review.

Data extraction
---------------

For original research articles meeting the selection criteria, study-level specifics, methodology, and discontinuation data were extracted. Study-level specifics consisted of publication details, study type, data source, participant characteristics, medications of interest, and the geographic location of the study population. Methodology-related data included the patient selection criteria and the time frame for outcome measurement in each specific study. Discontinuation data included definitions of measures, estimates, and reasons (including nonadherence and switching), if available.

For publications reporting expert opinions (reviews, meta-analyses, editorials/commentaries, and treatment guidelines), geographic location, study population, treatment(s) of interest, and reasons and recommendations for medication discontinuation were recorded.

Data synthesis
--------------

Data were synthesized for the following three outcomes: 1) persistence/discontinuation; 2) adherence; and 3) reasons for discontinuation (including nonadherence and switching). Persistence was evaluated for patients remaining on therapy and was defined as the time between treatment initiation and discontinuation, while adherence was generally defined based on the proportion of time a patient took a prescribed ADHD medication according to its dosage schedule.

A qualitative summary was constructed for persistence/discontinuation studies based on pharmacy refill records/databases, as well as on patient and parent/caregiver surveys. A quantitative analysis was performed using data that originated from the subset of persistence/discontinuation studies that implemented comparable measure definitions and follow-up periods. For various patient subgroups, pooled estimates of treatment duration were calculated as the weighted average across studies by sample size. These pooled estimates were then compared by patient age group, medication class (stimulants versus nonstimulants), formulation (long-acting \[LA\] versus short-acting \[SA\]), and stimulant type (AMPH versus MPH).

A qualitative summary was constructed for the adherence studies (pharmacy refill records/databases, patient and parent/caregiver surveys, and physician assessments) using the level or percentage of patients classified as adherent to ADHD medications. For the subset of adherence studies using comparable measure definitions and follow-up periods, a quantitative analysis was conducted by computing average adherence rates for patient subgroups weighted by sample size. Pooled treatment durations were then compared by age group, medication class, formulation, and stimulant type.

It should be noted that, when interpreting persistence and adherence to medication in the child/adolescent population, drug holidays, which refers to being temporarily off the prescribed medication during nonschool days, should be taken into consideration. Persistence and adherence might be underestimated when their measures were defined without considering drug holidays.

Qualitative summaries were constructed to display the treatment discontinuation reasons extracted from original research and expert opinion articles. Reasons for discontinuation were reported from the patients', parent/caregivers', and clinicians' perspectives and were compared by age group, medication class, and geographic location. The summary encompassed a broad range of discontinuation-related information, including type of discontinuation (permanent or temporary), motivation for switching, and reasons for nonadherent behavior. The reasons for discontinuation were ranked based on reporting frequency across the final set of studies. The ability to conduct quantitative comparisons using these data was limited, owing to differences in discontinuation reason descriptions and heterogeneity across study populations.

Results
=======

Systematic literature search
----------------------------

The initial literature search yielded 1,384 citations. Following the level I screening, 452 publications and an additional eleven studies identified through the citation search were included for full text review. The full text screening identified 127 publications meeting all selection criteria ([Figure 1](#f1-ndt-10-1543){ref-type="fig"}). The final lists of publications are shown in [Table S2](#SD2-ndt-10-1543){ref-type="supplementary-material"} (original research studies) and [Table S3](#SD3-ndt-10-1543){ref-type="supplementary-material"} (expert opinion articles). Study-level specifics, methodology, and detailed persistence/discontinuation, and/or adherence information were extracted and analyzed for all 127 publications. Details of the number of studies conducted, stratified by age, medication class, and geographic location are summarized in [Table 2](#t2-ndt-10-1543){ref-type="table"}.

Persistence/discontinuation
---------------------------

A total of 67 studies reported findings on persistence/discontinuation: 52 were retrospective database analyses (based on health insurance claims, registries, or patient chart data) and 15 were patient or parent/caregiver surveys.

### Database studies

Within the 52 retrospective database studies, three types of persistence measures were reported: discontinuation or continuation/persistence rate; treatment duration; and switching rate. Discontinuation of the index medication was generally defined as a gap, typically 30 days or more, in refill activity after the theoretical end date of the previous prescription.

Considerable heterogeneity existed across methodologies and reported outcomes in the persistence/discontinuation literature, with the most significant differences occurring in the definition of discontinuation, where gap length varied from 15 to 180 days, [@b23-ndt-10-1543]--[@b25-ndt-10-1543] and study length varied from 60 days to 6 years.[@b26-ndt-10-1543],[@b27-ndt-10-1543] Given that persistence declines with time, reliable comparisons of discontinuation rate, treatment duration, or switching rate across studies with different study period lengths were not feasible.

#### Discontinuation or continuation/persistence rate

Thirty-seven studies reported discontinuation or continuation/persistence rates, defined as the proportion of patients who discontinued their index medication or the proportion of patients who continued treatment as prescribed. Of these studies, eleven reported discontinuation rates among combined groups of children, adolescents, and adults, one study focused on adults only,[@b28-ndt-10-1543] and 25 studies focused on children and adolescents only. Three studies[@b29-ndt-10-1543]--[@b31-ndt-10-1543] reported results separately for those patients who were 18 years and under and for those \>18 years of age.

Substantial differences in target medication classes existed across the persistence/discontinuation studies. Six studies examined discontinuation rates among nonstimulant users (ATX; guanfacine immediate release \[GIR\]; GXR; or clonidine users), while 16 studies reported discontinuation rates for stimulants only. Fifteen studies reported rates for both stimulants and nonstimulants. Four studies[@b8-ndt-10-1543],[@b29-ndt-10-1543],[@b32-ndt-10-1543],[@b33-ndt-10-1543] reported results separately for stimulants and nonstimulants.

ADHD treatment discontinuation rates were reported in ten studies with a follow-up period of 12 months. Discontinuation rates for stimulants ranged from 19.1% for LA stimulant users of all ages[@b29-ndt-10-1543] to 99% for SA MPH pediatric (6--12 years old) users.[@b34-ndt-10-1543] Discontinuation rates for nonstimulants, reported from two studies on the use of ATX, ranged from 26.0% for 6--17 year old Italian patients[@b33-ndt-10-1543] to 38.3% for 2.5--90 year old Canadians (in Quebec).[@b29-ndt-10-1543]

#### Treatment duration

Thirteen studies reported treatment duration as the time during which patients remained on initial ADHD therapy until they discontinued. Of these, five studies[@b35-ndt-10-1543]--[@b39-ndt-10-1543] ([Table 3](#t3-ndt-10-1543){ref-type="table"}) employed the same definition of treatment duration -- the number of days that a patient remained on his or her initial therapy during a 12-month follow-up period -- and termination, which was defined as a gap of at least 30 days in prescription-filling activity. Of these studies, only four were used to create a pooled estimate ([Table 4](#t4-ndt-10-1543){ref-type="table"}), because two studies[@b38-ndt-10-1543],[@b39-ndt-10-1543] were kin studies. As Christensen et al[@b38-ndt-10-1543] reported additional results for AMPH, this study was chosen to be used for the analysis of treatment duration. Pooling of persistence estimates was only feasible for the children and adolescents population. Persistence ranged from 93.0 days (for SA stimulants) to 166.5 days (for AMPH). Only one study[@b38-ndt-10-1543] examined treatment duration among adults, reporting a range from 182.9 days (for MPH) to 252.7 days (for AMPH). The range of treatment duration reported for the overall age group was from 154.3 days (for nonstimulant ATX) to 254.2 days (for stimulants).

#### Switching

Switching to another medication was reported in 19 studies as either the rate of switching or the time to medication switch. Of these, six studies[@b23-ndt-10-1543],[@b38-ndt-10-1543]--[@b42-ndt-10-1543] used a follow-up length of 12 months; the rate of switching in these studies ranged from 3.7% for patients \<18 years old (switching from stimulants to nonstimulants)[@b38-ndt-10-1543] to 59% for children aged 6--12 years (switching from SA MPH to an unspecified ADHD medication).[@b23-ndt-10-1543]

### Patient and parent/caregiver surveys

Fifteen studies used patient or parent/caregiver interviews and surveys to assess persistence on ADHD medication. Of these, one study[@b43-ndt-10-1543] examined stimulant use among adults, while the remainder focused on ADHD pharmacotherapy among children and adolescents.

Discontinuation or continuation/persistence rates were reported in 13 of the studies. Among children and adolescents, discontinuation rates ranged from 11.1% for 8--18 year old patients, who stopped stimulant use following an average treatment duration of 3.3 years,[@b44-ndt-10-1543] to 96.4% for 4--17 year old Puerto Ricans taking stimulants, and who were observed over a 1-year period.[@b45-ndt-10-1543] Treatment duration was reported in three survey-based studies[@b46-ndt-10-1543]--[@b48-ndt-10-1543] and ranged from 79 days to 2.5 years; however, each study had a different follow-up length. Treatment switching was reported in one parent survey of Taiwanese children; the study found that 57% of patients classified as poor adherents switched from SA to LA MPH.[@b49-ndt-10-1543]

Adherence
---------

A total of 26 studies reported adherence results, of which 13 were retrospective database analyses, ten were patient or parent/caregiver surveys, and three were physician surveys.

### Database studies

Twelve database studies used health insurance claims data from North American sources; only one study was conducted outside this region.[@b32-ndt-10-1543] Overall, six studies examined adherence in combined populations of children, adolescents, and adults,[@b29-ndt-10-1543],[@b30-ndt-10-1543],[@b38-ndt-10-1543],[@b39-ndt-10-1543],[@b42-ndt-10-1543],[@b50-ndt-10-1543] while the remaining seven focused on adherence among children and adolescents only. Seven studies presented adherence results for both stimulants and nonstimulants, with each reported separately. Five studies assessed adherence to stimulant medications only (AMPH or MPH),[@b24-ndt-10-1543],[@b30-ndt-10-1543],[@b50-ndt-10-1543]--[@b52-ndt-10-1543] and one study examined adherence to nonstimulants only (ie, GIR and GXR).[@b53-ndt-10-1543]

All studies evaluated adherence as the number of days of medication supplied during a prespecified period. Ten studies defined adherence based on medication possession ratios (MPRs: the ratio of the number of days with medication supply to the total number of days in a defined period), while three studies employed days in possession ratio (DPR),[@b30-ndt-10-1543] annualized prescribed days,[@b54-ndt-10-1543] and proportion of days covered (PDC).[@b42-ndt-10-1543] MPR was reported as a continuous measure of adherence in six studies and as a categorical variable (adherence defined by a given threshold value) in six studies. Of the latter, four studies defined being adherent as having an MPR of \>0.8,[@b29-ndt-10-1543],[@b37-ndt-10-1543],[@b39-ndt-10-1543],[@b50-ndt-10-1543] while two employed an adherence threshold of 0.7.[@b51-ndt-10-1543],[@b52-ndt-10-1543]

Similar to the persistence/discontinuation studies, the length of study period varied across the 13 database studies, ranging from 3 months to \>2 years. The most commonly used study period was 12 months (six studies),[@b32-ndt-10-1543],[@b37-ndt-10-1543]--[@b39-ndt-10-1543],[@b42-ndt-10-1543],[@b54-ndt-10-1543] followed by 6 months (three studies)[@b24-ndt-10-1543],[@b30-ndt-10-1543],[@b53-ndt-10-1543] ([Table 5](#t5-ndt-10-1543){ref-type="table"}). As patients' adherence levels may change over longer study periods, results were interpreted in the context of their observation length.

A quantitative pooling of MPR results was conducted in which comparable study measures were determined for each of the following groups -- children and adolescents, adults, and the combined age group ([Table 6](#t6-ndt-10-1543){ref-type="table"}). Among the six studies measuring adherence during a 12-month period, only two unique studies used the same adherence definition, calculating MPR as the ratio of supply days to the total number of persistent days during the follow-up period.[@b32-ndt-10-1543],[@b38-ndt-10-1543],[@b39-ndt-10-1543] For the three studies using a 6-month period to measure adherence,[@b24-ndt-10-1543],[@b30-ndt-10-1543],[@b53-ndt-10-1543] only two studies used the same MPR definition[@b30-ndt-10-1543],[@b53-ndt-10-1543] -- the ratio of supply days to a fixed postindex period of 180 days ([Table 5](#t5-ndt-10-1543){ref-type="table"}). No pooled results could be estimated using these two studies, however, owing to the lack of a common treatment arm (each study examined a different medication class) ([Table 6](#t6-ndt-10-1543){ref-type="table"}).

#### Children and adolescents

A total of 12 studies reported adherence results for patients aged ≤18 years. For the eight studies in this group using MPR, PDC, or DPR, adherence ranged from 0.28 for treatment-experienced patients receiving SA MPH for 12 months to 0.76 for patients receiving LA MPH for 6 months.[@b24-ndt-10-1543],[@b42-ndt-10-1543] For studies using an MPR cut-off of 0.8, the rate of adherence ranged from 9.8% (for patients using SA stimulants for 12 months) to 64% (for patients receiving stimulants and/or nonstimulants for 12 months).[@b32-ndt-10-1543],[@b37-ndt-10-1543]

From the studies using a 12-month period, the pooled MPR for children and adolescents ranged from 0.56 for LA stimulants and AMPH to 0.67 for a nonstimulant (ATX). For the studies using a 6-month period, the pooled MPR ranged from 0.40 for SA stimulants to 0.61 for nonstimulants (GXR and GIR) ([Table 6](#t6-ndt-10-1543){ref-type="table"}). Similar to the persistence analysis, the quantitative analysis for adherence was limited by the small number of studies sharing the same follow-up period and measure definitions.

#### Adults

Five studies reported adherence results for adults separately, using MPR, PDC, or DPR.[@b29-ndt-10-1543],[@b30-ndt-10-1543],[@b38-ndt-10-1543],[@b39-ndt-10-1543],[@b42-ndt-10-1543] Among the four studies that presented continuous measures of adherence,[@b30-ndt-10-1543],[@b38-ndt-10-1543],[@b39-ndt-10-1543],[@b42-ndt-10-1543] adherence ranged from 0.30 for treatment-experienced patients receiving SA MPH for 12 months[@b42-ndt-10-1543] to 0.62 for patients receiving LA AMPH for 12 months.[@b38-ndt-10-1543] Pooling MPR results across adult ADHD studies was not feasible due to a lack of comparability of MPR definitions and study period lengths ([Table 6](#t6-ndt-10-1543){ref-type="table"}).

### Patient and parent/caregiver surveys

A total of ten studies conducted surveys and/or interviews to elicit assessments on medication adherence from patients with ADHD and their parents/caregivers. Two studies assessed adherence among adult patients with ADHD,[@b43-ndt-10-1543],[@b55-ndt-10-1543] while the remaining eight focused on child and adolescent populations. Compared with database studies on adherence, patient and parent/caregiver surveys were conducted over a wider geographic area: two in the US;[@b56-ndt-10-1543],[@b57-ndt-10-1543] three in Taiwan;[@b49-ndt-10-1543],[@b58-ndt-10-1543],[@b59-ndt-10-1543] and the remaining five in Norway,[@b43-ndt-10-1543] India,[@b60-ndt-10-1543] Spain,[@b55-ndt-10-1543] Canada,[@b61-ndt-10-1543] and Saudi Arabia.[@b62-ndt-10-1543] Two studies reported combined adherence on both stimulants and nonstimulants,[@b60-ndt-10-1543],[@b62-ndt-10-1543] while the remainder looked only at stimulants. While all ten studies yielded similar adherence trends, multiple differences existed in study design and execution, limiting cross-comparison of results.

Of the ten survey studies, three compared adherence between LA and SA stimulants.[@b43-ndt-10-1543],[@b49-ndt-10-1543],[@b55-ndt-10-1543] Among these three studies, LA stimulants were found to have better adherence (ranging between 74.3% and 97.1%)[@b49-ndt-10-1543],[@b55-ndt-10-1543] than SA stimulants (ranging between 42.9% and 60.0%).[@b43-ndt-10-1543],[@b49-ndt-10-1543] Definitions of adherence varied widely across these studies.

### Physician surveys

Three studies used physician-estimated measures for adherence and treating physicians were asked to rate patient adherence on a questionnaire. Definitions of adherence varied widely across all three studies (eg, physicians' belief on whether patients were consistently compliant;[@b63-ndt-10-1543] identification of patients who were \>80% adherent to treatment during weekdays and \>50% adherent during weekends and holidays;[@b64-ndt-10-1543] or application of a 6-point scale to rate adherence[@b65-ndt-10-1543]). Thus, adherence rates ranged between 57.1% (African--American youths in the US rated as consistently compliant to stimulants over 2 years)[@b63-ndt-10-1543] and 71.4% (for 6--17 year old western European patients with ADHD evaluated for a minimum of 2 years postdiagnosis).[@b64-ndt-10-1543] As with prior adherence assessments, this analysis was limited by the heterogeneity of methodologies across studies and by small sample sizes.

Reasons for treatment discontinuation
-------------------------------------

The literature search identified 41 original real-world studies ([Table S2](#SD2-ndt-10-1543){ref-type="supplementary-material"}) and 36 expert opinion articles ([Table S3](#SD3-ndt-10-1543){ref-type="supplementary-material"}) reporting reasons for treatment discontinuation. Among the 41 original studies, 30 (73%) reported reasons for discontinuation, seven (17%) reported reasons for nonadherence, and seven (17%) reported reasons for switching. Among the 36 expert opinion articles, 19 (53%) reported reasons for discontinuation, while 24 (67%) reported reasons for nonadherence, along with strategies to improve adherence. The following analysis of the reasons for discontinuation encompassed a broad range, including the type of discontinuation (permanent discontinuation of a medication or temporary discontinuation, such as a drug holiday), motivation for switching, and reasons for nonadherent behavior.

### Reasons for discontinuation from original research studies

The most common reasons for discontinuing ADHD medications were adverse effects (reported in 30 out of 41 studies) and ineffective symptom control/suboptimal response (in 27 out of 41 studies) ([Table 7](#t7-ndt-10-1543){ref-type="table"}). The studies were classified by age group and then analyzed by medication class, geographic region, and perspective for each age group.

#### Children and adolescents

Thirty-one (76%) studies focused on reasons for discontinuing treatment among children and adolescents. The two most frequently reported discontinuation reasons for children and adolescents were adverse effects and treatment ineffectiveness/suboptimal response (each reported in 21 out of 31 studies). Children and adolescents also frequently discontinued treatment due to poor adherence, parent/caregiver's decision to discontinue, and feeling that treatment was not needed due to symptom relief. Other reported reasons included patient attitude/dislike of medication, inconvenience of dosing, and the social stigma associated with ADHD and psychiatric medication, all of which are relevant in a school environment and might potentially explain children and adolescents' difficulty remaining on the medication.

Discontinuation reasons for children and adolescents treated with stimulants were extracted from 18 studies. The frequently cited reasons were: adverse effects; treatment ineffectiveness/suboptimal response; and poor adherence (each reported in more than five out of 18 studies). Other factors -- such as symptom control, parent/caregiver's decision to discontinue, dislike of medication, and dosing inconvenience -- were reported less frequently. Discontinuation reasons for children and adolescents treated with nonstimulants were detailed in only four studies.[@b66-ndt-10-1543]--[@b69-ndt-10-1543] All four of these studies cited treatment ineffectiveness/suboptimal response, three cited adverse effects, and one cited poor adherence to treatment as reasons for discontinuation. For both medication classes, patient attitude was also a reason for discontinuation, although it was not frequently reported. For children and adolescents living in North America (ten studies), the primary reason for discontinuation was experiencing adverse effects (reported in seven out of ten studies), followed by treatment ineffectiveness/suboptimal response, dislike of medication, symptom relief, and the parent/caregiver's decision to discontinue (each reported in more than two out of ten studies). In Europe (15 studies), treatment ineffectiveness/suboptimal response was the main reason for discontinuation (reported in 14 out of 15 studies), followed by adverse effects, poor adherence, symptom control, and dosing inconvenience. Among the studies reporting discontinuation reasons from both the patient's and the parent/caregiver's perspective (14 studies), the top three discontinuation reasons were adverse effects, treatment ineffectiveness/suboptimal response, and parent/caregiver's decision to discontinue (each reported in more than four out of 14 studies). Studies reporting discontinuation reasons from the physician's perspective (14 studies) recounted the same top two reasons, and added poor patient adherence as the third most common reason.

Five of the 41 discontinuation studies (12%) reported discontinuation reasons for children, adolescents, and young adults who were \<23 years old. The overall results for this age group were similar to the patterns observed in children and adolescents, but one study reported lack of information about ADHD as the reason for discontinuation. All five studies focused on stimulants as a class or on MPH only. Owing to the small number of studies, information on other subgroups based on geographic region and perspective was sparse.

#### Adults

Only five (12%) discontinuation studies covered treatment discontinuation reasons in adults. Of these studies, four focused on stimulants.[@b28-ndt-10-1543],[@b36-ndt-10-1543],[@b43-ndt-10-1543],[@b70-ndt-10-1543] The most common reasons for discontinuation were adverse effects and treatment ineffectiveness/suboptimal response (reported in three out of four studies). Other reported reasons included: achievement of symptom relief; misuse of medication; and the patient's decision to discontinue medication. Due to the small number of studies, information on other subgroups based on geographic region and perspective were sparse.

### Reasons for discontinuation based on expert opinions

The literature review identified 36 expert opinion articles on ADHD treatment discontinuation ([Table S3](#SD3-ndt-10-1543){ref-type="supplementary-material"}). The five most frequently encountered reasons for discontinuation were: adverse effects; dosing inconvenience; social stigma associated with ADHD and psychiatric medication; patient attitude; and treatment ineffectiveness/suboptimal response ([Table 8](#t8-ndt-10-1543){ref-type="table"}).

When discontinuation reasons were analyzed by age group, children and adolescents (67% of expert opinion studies) were shown to have similar reasons as those for the overall population analysis -- adverse effects, dosing inconvenience, patient attitude, social stigma, and patient--physician communication. Commonly cited reasons for discontinuation of stimulant use by children and adolescents (12 studies) included: adverse effects, patient attitude, dosing inconvenience, social stigma, and patient--physician communication (each reported in more than three out of 12 studies). Other reasons included: difficulties in swallowing, disorder-related factors, inadequate monitoring, and treatment ineffectiveness/suboptimal response. No study reported discontinuation reasons for nonstimulants. The top five discontinuation reasons cited by experts in North America (17 studies) were: adverse effects, dosing inconvenience, patient attitude, social stigma, and patient--physician communication. Experts in Europe (five studies)[@b71-ndt-10-1543]--[@b75-ndt-10-1543] provided similar reasons, with communication being replaced by inadequate monitoring.

In the only study from North America providing data on adult patients with ADHD (3%),[@b76-ndt-10-1543] adverse effects, social stigma, and dosing inconvenience were listed as the reasons for discontinuation.

In the combined age group (30% of expert opinion studies), six studies focused on stimulant discontinuation,[@b65-ndt-10-1543],[@b77-ndt-10-1543]--[@b81-ndt-10-1543] and adverse effects were cited as a discontinuation reason in five of them.[@b77-ndt-10-1543]--[@b81-ndt-10-1543] Other reasons given by experts for discontinuing stimulants included: treatment ineffectiveness/suboptimal response; difficulties in swallowing; dosing inconvenience; forgetfulness; and social stigma. No study provided discontinuation reasons for nonstimulants. Adverse effects and treatment ineffectiveness/suboptimal response were consistently referred to as the main reasons for discontinuation in the combined age group of children, adolescents, and adults by experts in North America (seven studies) and Europe (two studies).[@b65-ndt-10-1543],[@b77-ndt-10-1543] Experts from North America also cited: dosing inconvenience; forgetfulness; patient attitude, difficulties in swallowing, and social stigma as reasons for discontinuation. No additional reasons were provided by experts in Europe.

Discussion
==========

This literature review examined persistence and adherence to pharmacologic treatment for ADHD and summarized reasons for treatment discontinuation. Where feasible, the analyses were also stratified across subgroups of patients by age group, geographic location, and medication class. Overall, findings from this study indicate that persistence and adherence to ADHD treatment were generally low and that tolerability was cited as an important reason for treatment discontinuation.

In our review of persistence studies, we observed that there was significant heterogeneity in measures of persistence in studies using patient/caregiver and physician surveys. The issue also affected retrospective database analyses, although to a lesser extent. Most of these studies measured persistence as time to a predefined prescription gap. However, variation in gap lengths and follow-up periods still exists. Rates of treatment persistence varied (between 0.1% and 89.9%), depending on definitions across studies. Despite the variations, higher persistence was observed in patients using LA than SA stimulants.

Definitions of adherence were largely based on the number of days of medication supply. For all three types of studies examined -- database studies, patient and parent/caregiver surveys, and physician surveys -- adherence measure definitions and follow-up periods varied widely. Most studies reported rates of \<80% (or a mean MPR of \<0.8),[@b82-ndt-10-1543] indicating a low treatment adherence for the ADHD population. From a societal perspective, it is often important to compare adherence across chronic diseases to help payers and policymakers understand how the adherence and its potential impact in one condition is relative to other similar conditions of interest. In general, adherence to ADHD medication was comparable with estimates reported for other psychiatric (schizophrenia, bipolar disorder)[@b83-ndt-10-1543]--[@b85-ndt-10-1543] and nonpsychiatric chronic disorders (hyperlipidemia, diabetes, hypertension, etc)[@b82-ndt-10-1543],[@b86-ndt-10-1543],[@b87-ndt-10-1543] with low adherence. There was no clear evidence that any subgroups (by age or medication class) experienced higher adherence than the others, but, in general, children and adolescents seemed to display higher adherence to nonstimulant than to stimulant medications. Adult adherence rates to various stimulant subcategories,[@b30-ndt-10-1543],[@b38-ndt-10-1543] as measured by MPR, suggest that patients on AMPH may have had higher adherence than those taking MPH; however, more comparable studies are needed to validate these results. The adherence estimates were not influenced by the length of the observation periods (eg, 6 months or 12 months).

This systematic literature review identified numerous reasons for discontinuation of ADHD medication. The most commonly cited reason for discontinuation in original research studies and expert opinion reviews was experiencing some adverse effects from the ADHD medication, regardless of age group, medication class, region, prior treatment status, and reporting perspective. Other reasons for discontinuation were generally similar across these two study types, although some differences were worth noting. Ineffectiveness/suboptimal response was one of the most commonly reported reasons in the original studies, but it was reported less frequently in the expert opinion reviews (although it was still within the top five discontinuation explanations). Similarly, poor adherence was a commonly cited reason in the original studies but not in expert opinion reviews. In contrast, dosing inconvenience and social stigma were among the top five reasons in the expert opinion articles, but they were rarely reported in the original studies. Among adults, symptom relief, concerns over drug misuse, and desire to terminate treatment were frequent motivators. Among children and adolescents, discontinuation often occurred due to symptom relief, but also as a result of poor adherence or the parent/caregiver's decision to discontinue.

This study observed a number of limitations in the existing body of evidence. First, due to the heterogeneity of study designs and methodology, the scope of a quantitative synthesis of persistence and adherence was limited. In the final quantitative analysis, the selection of eligible articles was narrowed down to a small list of directly comparable studies, which limited the generalizability of our conclusions. Second, the majority of original studies discussed reasons for discontinuation without reporting the proportion of patients affected by each reason; therefore, the rank of discontinuation reasons was based on frequencies of being reported in published studies. It was unclear whether most patients discontinued treatment due to the most frequently reported reasons in the literature. Third, reporting bias may exist as this study did not assess scientific quality of the included studies. Another limitation is related to the adverse effects that were reported to be the main reason for discontinuation across studies. The majority of studies did not provide details on the specific adverse effects that led to discontinuation. Hence, it was not clear if a particular side effect was responsible for a patient's unwillingness to continue treatment or if generally experiencing some unexpected or unpleasant side effect was sufficient to prompt treatment discontinuation.

Among the 91 original observational studies, only eleven studies reported adherence or discontinuation results for the adult ADHD population and, of these, only five original studies provided information on the underlying reasons for treatment discontinuation. Reasons for discontinuation for adults were provided in only one expert opinion article. This limited information on adherence and persistence in adults is one of the key findings and a call for action for further research to understand the adherence and persistence in the adult population.

Another important aspect of ADHD treatment is drug holidays (scheduled temporary suspensions of pharmacologic treatment). In this analysis, drug holidays were not always considered in studies of children and adolescents with ADHD. Stimulant-treated minors are often advised to take drug holidays during their school holidays or, sometimes, even weekends. Thus, observational database studies using persistence and adherence measures based on commonly used treatment gaps of 30 days may not have taken drug holidays into consideration and may have overestimated the rate of discontinuation -- a type of attribution bias. Similarly, database studies measuring adherence as MPRs considered drug holidays as nonadherent days and, therefore, the adherence was underestimated in these studies.

Treatment adjustment is a common phenomenon with ADHD medication, and it should be taken into account when studying adherence and persistence measures. For example, the lower adherence and persistence with SA versus LA stimulants observed in the study could be attributed to a dose titration process. Patients initiating ADHD treatment are often started with low doses and then they titrate to an optimal dosage over time, to maximize medication effectiveness and minimize adverse effects.[@b88-ndt-10-1543],[@b89-ndt-10-1543] SA stimulants may be used for the first titration[@b90-ndt-10-1543] and, then, if the duration of effect of the optimized dosage is not adequate, patients are typically switched to LA formulations.

Over the past few decades, as ADHD knowledge has advanced, the use of alternative treatment modalities, such as the use of nonstimulants as adjunctive therapies to the core stimulant regimen for patients with suboptimal response to stimulant monotherapy, has increased. As ADHD care has evolved, so too should research into the adherence/persistence of these alternative treatment approaches.[@b91-ndt-10-1543] Two nonstimulants have been approved in the US and Canada for adjunctive use.[@b92-ndt-10-1543],[@b93-ndt-10-1543] However, no observational study was identified in this systematic review evaluating persistence/discontinuation and adherence of nonstimulants as adjunctive therapies; these newer treatment modalities may have different usage and outcome patterns compared with ADHD monotherapy.

Finally, differences in treatment settings (specialist versus generalist care) could not be considered in the scope of this review, as it was not reported consistently. Such differences could influence the reporting of specific discontinuation reasons across varying study types. For example, expert opinions may have been written by experienced child psychiatrists, who are more familiar with pharmacological treatment of ADHD -- and in particular with stimulants.[@b94-ndt-10-1543] In addition, they may also have access to multiprofessional teams, facilitating patient management through multimodal treatment options, including continuous psychoeducation, cognitive behavioral therapy, parent training, etc. Thus, these practitioners may be less concerned about ineffectiveness/suboptimal response, as observed in our review. In contrast, physician survey studies could potentially include primary care physicians and pediatricians, who may be less familiar with medical treatment regimens for ADHD and thus may exhibit greater concerns regarding ineffectiveness/suboptimal response of the treatment.

These limitations highlight some gaps in the existing literature and provide possible directions for future research. Studies using comparable definitions and follow-up periods for different subgroups of patients with ADHD are needed to fill the current knowledge gap on the actual rates of adherence to pharmacologic treatment for ADHD. In particular, the current review confirms that treatment patterns in adult ADHD are poorly understood and that further studies are still required to shed light on how disease management approaches in this population will be different from that in children and adolescents. Similarly, systematic comparisons across other subgroups based on medication class (stimulants versus nonstimulants) and formulations (LA versus SA) should also be considered to inform what treatment strategies should be adopted to maintain persistence and adherence for these subgroups. In addition, with the increasing use of adjunctive therapies in the treatment of ADHD, disease management can also benefit from more real-world evidence on the treatment patterns of adjunctive therapies. Large observational studies in which patients are closely followed could provide more reliable estimates of treatment persistence and adherence. Future research that comprehensively collects reasons for discontinuation of ADHD treatment -- adjusted for differences in treatment settings, age groups, and medication type -- is warranted and will help patients and clinicians choose, monitor, and improve future ADHD treatment regimens.

Conclusion
==========

In this systematic literature review and analysis, persistence and adherence to pharmacologic treatments for ADHD were generally inadequate. The highest persistence was generally observed for patients taking LA stimulants (compared with all other formulations) although further comparative studies are needed. The most common reasons for discontinuation extracted from original studies included adverse effects of ADHD medication, treatment ineffectiveness/suboptimal response, and poor patient adherence to treatment. According to expert opinions, the main reasons for discontinuing ADHD medication were adverse effects of medication, dosing inconvenience, and social stigma associated with ADHD and psychiatric disorders in general. The findings suggest that although efficacy, social factors, convenience, and patient attitude may influence treatment adherence and discontinuation, tolerability remains the most important component to consider when deciding on a treatment regimen. Based on these findings, clinicians may be able to help improve treatment adherence and persistence in this chronic disease by educating caregivers and patients on treatment goals, administering LA medications, and continuing to closely follow-up with patients to verify if medication is still effective and well-tolerated and to ensure medication is switched when there are tolerability issues or lack of symptom control.

Supplementary materials
=======================

###### 

A list of ADHD medications approved in North American and European countries

  Stimulants/nonstimulants                                                           Medication class                                     ADHD medications (Medication type, Formulation if available, Manufacturer)
  ---------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------
  Nonstimulants                                                                      Selective norepinephrine reuptake inhibitor          Strattera^®^ (ATX; Eli Lilly and Company)
  Atomoxetine Teva (ATX; Teva)                                                                                                            
  Alpha-2 adrenergic agonist                                                         Intuniv^®^ (GXR; Shire)                              
  Guanfacine/Guanfasiini immediate release (GIR)                                                                                          
  Kapvay^®^ (clonidine hydrochloride, extended release; Concordia Pharmaceuticals)                                                        
  Clonidine immediate release (CIR)                                                                                                       
  Stimulants                                                                         Methylphenidate                                      Biphentin^®^ (MPH; Perdue Pharma)
  Concerta^®^ (MPH; Janssen Pharmaceuticals/ALZA Corporation)                                                                             
  Daytrana^®^ (MPH; Noven Therapeutics)                                                                                                   
  Elmifiten^®^ (dexmethylphenidate; Alfred E Tiefenbacher Gmbh & Co.)                                                                     
  Equasym XL^®^/Equasym Retard^®^/Equasym Depot^®^/Quasym LP^®^ (MPH; Shire)                                                              
  Focalin^®^ (dexmethylphenidate; Novartis)                                                                                               
  Focalin XR^®^ (dexmethylphenidate, extended release; Novartis)                                                                          
  Metadate^®^ (MPH; UCB Pharma)                                                                                                           
  Metadate CD^®^ (MPH, extended release capsules; UCB Pharma)                                                                             
  Metadate ER^®^ (MPH, extended release tablets; UCB Pharma)                                                                              
  Medicebran^®^ (MPH; Laboratorios Farmacéuticos Rovi)                                                                                    
  Medikid (MPH)                                                                                                                           
  Medikinet/Medikinet CR^®^ (MPH; Medice)                                                                                                 
  Medikinet^®^ XL (MPH; Medice)                                                                                                           
  Medikinet Retard^®^ (MPH; Medice)                                                                                                       
  Methylin^®^ (MPH; Mallinckrodt/Shionogi)                                                                                                
  Methylin ER^®^ (MPH, extended release; Mallinckrodt/Shionogi)                                                                           
  Methylphenidat-1A pharma^®^ (MPH; 1 A Pharma)                                                                                           
  Methylphenidat HEXAL^®^ (MPH; Hexal)                                                                                                    
  Methylphenidat-ratiopharm^®^ (MPH; Ratiopharm)                                                                                          
  Methylpheni TAD^®^ (MPH; TAD Pharma GmbH)                                                                                               
  Methylphenidat TB (MPH; Alfred E Tiefenbacher GmbH & Co.)                                                                               
  Methylfenidaat HCl (MPH, hydrochloride)                                                                                                 
  Methylfenidaat HCI AET (MPH, hydrochloride; Alfred E Tiefenbacher GmbH & Co.)                                                           
  Motiron^®^ (MPH; Sandoz)                                                                                                                
  Methylphenidate Rubio (MPH; Laboratorios Rubió)                                                                                         
  Omozin^®^ (MPH; Laboratorios Rubió)                                                                                                     
  Ritalin/Ritaline^®^ (MPH; Novartis)                                                                                                     
  Ritalin LA^®^ (MPH, long acting; Novartis)                                                                                              
  Ritalin SR^®^ (MPH, sustained release; Novartis)                                                                                        
  Rubifen^®^ (MPH; Laboratorios Rubió)                                                                                                    
  Tifinidat (MPH; Alfred E Tiefenbacher GmbH & Co.)                                                                                       
  Quillivant™ (MPH; Pfizer)                                                                                                               
  Quillivant XR™ (MPH, extended release; Pfizer)                                                                                          
  Amphetamine                                                                        Adderall^®^ (amphetamine/dextroamphetamine; Shire)   
  Adderall XR^®^ (AMPH/dextroamphetamine, extended release; Shire)                                                                        
  Dexedrine^®^ SR (dextroamphetamine, sustained release; Amedra Pharmaceuticals)                                                          
  Dexedrine^®^ spansules^®^ (dextroamphetamine; Amedra Pharmaceuticals)                                                                   
  Dextroamphetamine ER (dextroamphetamine, extended release)                                                                              
  Desoxyn^®^ (methamphetamine hydrochloride; Recordati Rare Diseases, INC.)                                                               
  Dexedrine^®^ (dextroamphetamine; Amedra Pharmaceuticals LLC)                                                                            
  Dextrostat^®^ (dextroamphetamine; Shire)                                                                                                
  Elvanse^®^ (lisdexamfetamine; Shire)                                                                                                    
  LiquADD^®^ (dextroamphetamine; Auriga Laboratories)                                                                                     
  Metamina (dexamfetamin)                                                                                                                 
  Vyvanse^®^ (lisdexamfetamine; Shire)                                                                                                    

**Notes:** Intuniv^®^ is approved in the US only; Biphentin^®^ is approved in Canada only; Attentin^®^ is approved in Germany only. Medikinet Retard^®^ (not Medikinet XL^®^) and Equasym Retard^®^ (not Equasym XL^®^) are approved in Germany. Equasym XL^®^ is marketed as Metadate CD^®^ in the US.

**Abbreviations:** ADHD, attention-deficit/hyperactivity disorder; ATX, atomoxetine; GXR, guanfacine extended release; GIR, guanfacine immediate release; CIR, clonidine immediate release; MPH, methylphenidate; AMPH, amphetamine.

###### 

List of included original observational studies and bibliographic information

  ID    Primary study citation                                                                                                                                                                                                                                                                                            Reported discontinuation reasons
  ----- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  A1    McCarthy S, Wilton L, Murray M, Hodgkins P, Asherson P, Wong IC. Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners. *Health Qual Life Outcomes*. 2013;11:22.                                                                                     Yes
  A2    Erder MH, Signorovitch JE, Setyawan J, et al. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. *J Med Econ*. 2012;15(6):1078--1087.                                                                                          No
  A3    Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. *Curr Med Res Opin*. 2011;27 Suppl 2:13--22.                                                                                                                                                   No
  A4    Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B. Exploring the impact of once-daily OROS^®^ methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. *Postgrad Med*. 2011;123(5):27--38.                   Yes
  A5    Mazzone L, Reale L, Mannino V, Cocuzza M, Vitiello B. Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. *CNS Drugs*. 2011;25(6):503--509.                                                                         Yes
  A6    Marcus SC, Durkin M. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2011;50(5):480--489.                                                                                                                        No
  A7    Fernández-Jaén A, Fernández-Mayoralas DM, Pardos A, Calleja-Pérez B, Muñoz Jareño N. Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation. *Adv Ther*. 2009;26(12):1097--1110.                                        Yes
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  A10   Gimpel GA, Collett BR, Veeder MA, et al. Effects of stimulant medication on cognitive performance of children with ADHD. *Clin Pediatr (Phila).* 2005;44(5):405--411.                                                                                                                                             No
  A11   Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. *J Child Adolesc Psychopharmacol*. 2004;14(4):575--581.                                                                                                                No
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Selection criteria of systematic review

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  **Inclusion criteria**                                                                                                                                                       **Publication type**
  • Full-text primary publications of real-world studies                                                                                                                       
  • Treatment guidelines for US, Canada, UK, Germany, France, Spain, Italy, Sweden, and the Netherlands -- as well as any general European guidelines                          
  • Editorials and commentaries                                                                                                                                                
  • Reviews (systematic and nonsystematic) and meta-analyses of real-world studies                                                                                             
  **Study design of real-world studies**                                                                                                                                       
  • Observational studies based on real-world data (cohort studies, including both prospective and retrospective designs, cross-sectional studies, and case-control studies)   
  • Phase IV clinical trials                                                                                                                                                   
  **Population**                                                                                                                                                               
  • At least 80% of study population (children, adolescents, or adults) have ADHD as the primary disorder                                                                      
  **Interventions**                                                                                                                                                            
  • ADHD drug treatment approved as of September 2013 by a regulatory agency in North America or Europe for ADHD in monotherapy or in combination therapy, ie:                 
   ○ Stimulants: MPH, AMPH/dexamphetamine, and lisdexamfetamine                                                                                                                
   ○ Nonstimulants: ATX, GXR, and clonidine extended release                                                                                                                   
  • Two off-label medications commonly used in ADHD:                                                                                                                           
   ○ GIR and CIR                                                                                                                                                               
  **Outcomes**                                                                                                                                                                 
  • Reported discontinuation/switching results, or                                                                                                                             
  • Reported reasons for discontinuation/switching of ADHD drug treatment                                                                                                      
  **Language:** English                                                                                                                                                        
  **Publication date:** During or after 1990                                                                                                                                   
  **Exclusion criteria**                                                                                                                                                       **Publication type**
  • Nonprimary publications of real-world studies (eg, a publication that has less data than the primary publication to report the same outcomes)                              
  • Conference abstracts or posters                                                                                                                                            
  • Congress proceedings                                                                                                                                                       
  • Books/chapters/addresses/bibliographies/biographies/lectures                                                                                                               
  • Case reports                                                                                                                                                               
  • Letters                                                                                                                                                                    
  • Treatment guidelines for countries other than: US, Canada, UK, Germany, France, Spain, Italy, Sweden, and the Netherlands                                                  
  • Reviews/meta-analyses not of real-world studies                                                                                                                            
  **Study design**                                                                                                                                                             
  • Preclinical studies                                                                                                                                                        
  • Clinical trials (Phase I--Phase III)                                                                                                                                       
  • Prognostic studies                                                                                                                                                         
  • Genetic studies                                                                                                                                                            
  **Population**                                                                                                                                                               
  • Nonhuman subjects                                                                                                                                                          
  • Not ADHD patients                                                                                                                                                          
  • \<80% of study population have ADHD as the primary disorder                                                                                                                
  **Intervention**                                                                                                                                                             
  • No drug treatment                                                                                                                                                          
  • Drug treatment not listed in the inclusion criteria                                                                                                                        
  **Outcomes**                                                                                                                                                                 
  • Does not report discontinuation/continuation results, and                                                                                                                  
  • Does not report reasons for ADHD medication discontinuation                                                                                                                
  **Language:** Non-English                                                                                                                                                    
  **Publication date:** Before 1990                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------

**Abbreviations:** ADHD, attention-deficit/hyperactivity disorder; MPH, methylphenidate; AMPH, amphetamine; ATX, atomoxetine; GXR, guanfacine extended release; GIR, guanfacine immediate release; CIR, clonidine immediate release.

###### 

Number of studies reporting results for subgroups

                                                                                                   \# of studies   
  ------------------------------------------------------------------------------------------------ --------------- ----
  **Outcome**                                                                                                      
  Persistence/discontinuation                                                                      67              NA
   Based on retrospective database                                                                 52              
   Based on patient and parent/caregiver surveys                                                   15              
  Adherence                                                                                        26              
   Based on retrospective database                                                                 13              
   Based on patient and parent/caregiver surveys                                                   10              
   Based on physician surveys                                                                      3               
  Reasons for discontinuation/nonadherence                                                         41              36
  **Population**                                                                                                   
  Children and adolescents                                                                         62              24
  Adults                                                                                           7               1
  Combined age group of children, adolescents, adults[a](#tfn2-ndt-10-1543){ref-type="table-fn"}   22              11
  **Drug class**                                                                                                   
  Stimulants                                                                                       56              18
  Nonstimulants                                                                                    7               0
  ADHD treatment including stimulants, nonstimulants[b](#tfn3-ndt-10-1543){ref-type="table-fn"}    28              18
  **Geographic location**                                                                                          
  North America                                                                                    45              25
  Europe                                                                                           33              7
  Other parts of the world                                                                         13              4

**Notes:**

Studies conducted in combined age group can report stratified results for children/adolescents or adults.

Studies that included ADHD treatment can report stratified results for stimulants or nonstimulants.

**Abbreviations:** NA, not applicable; ADHD, attention-deficit/hyperactivity disorder.

###### 

Studies included in quantitative analysis for persistence

  First author (year)                                                             Persistence measure   Definition                                                                                                                                                                                                                                                                                                                                                                         Age group                                                                          Treatment
  ------------------------------------------------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  Barner (2011)[@b37-ndt-10-1543]                                                 Treatment duration    Persistence was defined as number of days of continuous therapy (without a specified gap period) during the postindex period (12 months). Gap period was 30 days.                                                                                                                                                                                                                  Children and adolescents                                                           Stimulants (LA, SA; MPH, AMPH) and nonstimulants; results reported separately
  Palli (2012)[@b35-ndt-10-1543]                                                  Treatment duration    Persistence in terms of time to discontinuation of index medication; switching from one type of preparation within the stimulant class was allowed, but switching to another class was defined as discontinuation of index stimulant. All stimulant recipients were uniformly followed for 1 year (365 days). Gap period was 30 days.                                              Children and adolescents                                                           Stimulants (LA, SA); results reported separately
  Hodgkins (2011)[@b39-ndt-10-1543],[a](#tfn5-ndt-10-1543){ref-type="table-fn"}   Treatment duration    Persistence was defined as number of days (out of 366; follow-up period defined as index day plus 365 days) patient remained on initial therapy. Gap period was 30 days.                                                                                                                                                                                                           Combined age group of children, adolescents, adults; results reported separately   Stimulants (LA MPH; SA MPH); results reported separately
  Christensen (2010)[@b38-ndt-10-1543]                                            Treatment duration    Persistence was calculated as number of days out of 366 (follow-up period defined as index day plus 365 days) that patient remained on index therapy. Gap period was 30 days.                                                                                                                                                                                                      Combined age group of children, adolescents, adults; results reported separately   Stimulants (LA, SA; MPH, AMPH) and nonstimulant (ATX); results reported separately
  Marcus (2005)[@b36-ndt-10-1543]                                                 Treatment duration    Duration of MPH treatment episode for each patient was calculated by sequentially counting unduplicated continuous prescriptions using date of prescription and number of days of medications supplied. Episodes of treatment were considered to have terminated if a gap of 30 or more days occurred from end of last prescription supply and start of subsequent prescription.   Children and adolescents                                                           Stimulants (LA MPH; SA MPH); results reported separately

**Note:**

Hodgkins et al (2011)[@b39-ndt-10-1543] was excluded from the quantitative summary because it reported fewer results than Christensen (2010) and they both reported results from the same study.

**Abbreviations:** LA, long acting; SA, short acting; MPH, methylphenidate; AMPH, amphetamine; ATX, atomoxetine.

###### 

Persistence results (reported as mean treatment duration, in days) from quantitative analysis

  Age group                                             First author (year)               Stimulants   Nonstimulants   LA       SA       MPH       AMPH                                                  
  ----------------------------------------------------- --------------------------------- ------------ --------------- -------- -------- --------- -------- -------- -------- -------- -------- -------- --------
  Children and adolescents                              Barner (2011)[@b37-ndt-10-1543]   134.98       53,838          153.30   8,516    143.70    44,118   95.40    9,720    135.76   33,852   133.57   19,986
  Palli (2012)[@b35-ndt-10-1543]                        97.83                             46,135       NA              NA       104.96   33,561    79.97    8,260    NA       NA       NA       NA       
  Christensen (2010)[@b38-ndt-10-1543]                  232.39                            21,386       NA              NA       232.39   21,386    NA       NA       234.40   11,077   230.23   10,309   
  Marcus (2005)[@b36-ndt-10-1543]                       114.42                            11,537       NA              NA       140.30   3,444     103.40   8,093    114.42   11,537   NA       NA       
  Pooled                                                135.97                            132,896      153.30          8,516    149.41   102,509   92.99    26,073   150.75   56,466   166.46   30,295   
  Adults                                                Barner (2011)[@b37-ndt-10-1543]   NA           NA              NA       NA       NA        NA       NA       NA       NA       NA       NA       NA
  Palli (2012)[@b35-ndt-10-1543]                        NA                                NA           NA              NA       NA       NA        NA       NA       NA       NA       NA       NA       
  Christensen (2010)[@b38-ndt-10-1543]                  229.63                            10,906       NA              NA       229.63   10,906    NA       NA       182.90   3,604    252.70   7,302    
  Marcus (2005)[@b36-ndt-10-1543]                       NA                                NA           NA              NA       NA       NA        NA       NA       NA       NA       NA       NA       
  Pooled                                                229.63                            10,906       NA              NA       229.63   10,906    NA       NA       182.90   3,604    252.70   7,302    
  Combined age group of children, adolescents, adults   Barner (2011)[@b37-ndt-10-1543]   NA           NA              NA       NA       NA        NA       NA       NA       NA       NA       NA       NA
  Palli (2012)[@b35-ndt-10-1543]                        NA                                NA           NA              NA       NA       NA        NA       NA       NA       NA       NA       NA       
  Christensen (2010)[@b38-ndt-10-1543]                  254.20                            47,018       154.30          12,992   239.50   32,292    186.70   10,069   219.20   23,862   240.60   23,156   
  Marcus (2005)[@b36-ndt-10-1543]                       NA                                NA           NA              NA       NA       NA        NA       NA       NA       NA       NA       NA       
  Pooled                                                254.20                            47,018       154.30          12,992   239.50   32,292    186.70   10,069   219.20   23,862   240.60   23,156   

**Notes:** Treatment duration is defined as the number of days patients stayed on their initial therapy. All four studies use a gap period of 30 days.

**Abbreviations:** LA, long acting; SA, short acting; MPH, methylphenidate; AMPH, amphetamine; NA, not applicable.

###### 

Studies included in quantitative analysis for adherence

  First author (year)                                                             Adherence measure   Definition                                                                                                                                                                                                                                                               Age group                                                                          Treatment
  ------------------------------------------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  **12 months**                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Hodgkins (2011)[@b39-ndt-10-1543],[a](#tfn9-ndt-10-1543){ref-type="table-fn"}   MPR                 Ratio of number of days of initial therapy (sum of days supplied for all filled prescriptions while index therapy persisted, excluding days of supply of the fill that terminated persistence) to total number of days persistent. Observational period was 12 months.   Children and adolescents                                                           Stimulants (LA, SA; MPH, AMPH) and nonstimulant (ATX); results reported separately
  Hodgkins (2011)[@b32-ndt-10-1543]                                               MPR                 Ratio of total number of days for which the medication was supplied to total number of days supplied in that year. Observational period was 12 months.                                                                                                                   Combined age group of children, adolescents, adults; results reported separately   Stimulants (LA MPH; SA MPH); results reported separately
  Christensen (2010)[@b38-ndt-10-1543]                                            MPR                 Ratio of number of days of initial therapy (sum of days supplied for all filled prescriptions while index therapy persisted, excluding days of supply of the fill that terminated persistence) to total number of days persistent. Observation period was 12 months.     Combined age group of children, adolescents, adults; results reported separately   Stimulants (LA, SA; MPH, AMPH) and nonstimulant (ATX); results reported separately
  **Studies excluded owing to inconsistent measures of MPR**                                                                                                                                                                                                                                                                                                                                                                                                      
  Barner (2011)[@b37-ndt-10-1543]                                                 MPR                 Ratio of sum of days of supply to 365 days.                                                                                                                                                                                                                              --                                                                                 --
  Saloner (2013)[@b54-ndt-10-1543]                                                APD                 Ratio of days with prescribed medications multiplied by 365 to total days after first prescription. Observation period was 2 years.                                                                                                                                      --                                                                                 --
  Setyawan (2013)[@b42-ndt-10-1543]                                               PDC                 Ratio of number of days covered by prescribed index medication to 365 days.                                                                                                                                                                                              --                                                                                 --
  **6 months**                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Sikirica (2013)[@b53-ndt-10-1543]                                               MPR                 Ratio of sum of days of supply to days in 6-month study period.                                                                                                                                                                                                          Children and adolescents                                                           Nonstimulant (GIR, GXR)
  Lawson (2012)[@b30-ndt-10-1543]                                                 DPR                 Ratio of number of days in which patient possessed medication to 180 day postindex period.                                                                                                                                                                               Combined age group of children, adolescents, adults; results reported separately   Stimulants (LA, SA; MPH, AMPH); results reported separately
  **Studies excluded owing to inconsistent measures of MPR**                                                                                                                                                                                                                                                                                                                                                                                                      
  Sanchez (2005)[@b24-ndt-10-1543]                                                MPR                 Ratio of days of supply from index prescription to last prescription of study period to number of days patient optimally should have received medication. Observation period was 6 months.                                                                               --                                                                                 --

**Notes:**

Hodgkins (2011)[@b39-ndt-10-1543] was excluded from the quantitative summary, because it reported fewer results than Christensen (2010). They both reported results from the same study.

**Abbreviations:** MPR, medication possession ratio; LA, long acting; SA, short acting; MPH, methylphenidate; AMPH, amphetamine; ATX, atomoxetine; APD, annualized prescribed days; PDC, proportion of days covered; GIR, guanfacine immediate release; GXR, guanfacine extended release; DPR, days in possession ratio.

###### 

Adherence results (mean MPR) from quantitative analysis

  Age group                                                                   First author (year)                 Stimulants   Nonstimulants   LA       SA      MPH      AMPH                                              
  --------------------------------------------------------------------------- ----------------------------------- ------------ --------------- -------- ------- -------- ------ -------- ------- -------- ------- -------- ----
  **Study period of 12 months**[a](#tfn11-ndt-10-1543){ref-type="table-fn"}                                                                                                                                                
  Children and adolescents                                                    Hodgkins (2011)[@b32-ndt-10-1543]   0.64         4,801           0.67     81      0.66     419    0.64     4,382   0.64     4,775   0.56     26
  Christensen (2010)[@b38-ndt-10-1543]                                        0.56                                21,386       NA              NA       0.56    21,386   NA     NA       0.55    11,077   0.56    10,309   
  Pooled                                                                      0.57                                26,187       0.67            81       0.56    21,805   0.64   4,382    0.58    15,852   0.56    10,335   
  Adults                                                                      Hodgkins (2011)[@b32-ndt-10-1543]   NA           NA              NA       NA      NA       NA     NA       NA      NA       NA      NA       NA
  Christensen (2010)[@b38-ndt-10-1543]                                        0.59                                10,906       NA              NA       0.59    10,906   NA     NA       0.52    3,604    0.62    7,302    
  Pooled                                                                      0.59                                10,906       NA              NA       0.59    10,906   NA     NA       0.52    3,604    0.62    7,302    
  Combined age group of children, adolescents, adults                         Hodgkins (2011)[@b32-ndt-10-1543]   NA           NA              NA       NA      NA       NA     NA       NA      NA       NA      NA       NA
  Christensen (2010)[@b38-ndt-10-1543]                                        0.57                                47,018       0.49            12,992   0.56    32,292   0.43   10,069   0.53    23,862   0.57    23,156   
  Pooled                                                                      0.57                                47,018       0.49            12,992   0.56    32,292   0.43   10,069   0.53    23,862   0.57    23,156   
  **Study period of 6 months**                                                                                                                                                                                             
  Children and adolescents                                                    Sikirica (2013)[@b53-ndt-10-1543]   NA           NA              0.61     3,087   NA       NA     NA       NA      NA       NA      NA       NA
  Lawson (2012)[@b30-ndt-10-1543]                                             0.49                                14,457       NA              NA       0.50    13,108   0.40   1,349    0.49    10,440   0.49    4,017    
  Pooled                                                                      0.49                                14,457       0.61            3,087    0.50    13,108   0.40   1,349    0.49    10,440   0.49    4,017    
  Adults                                                                      Sikirica (2013)[@b53-ndt-10-1543]   NA           NA              NA       NA      NA       NA     NA       NA      NA       NA      NA       NA
  Lawson (2012)[@b30-ndt-10-1543]                                             0.49                                586          NA              NA       0.47    450      0.56   136      0.45    267      0.53    319      
  Pooled                                                                      0.49                                586          NA              NA       0.47    450      0.56   136      0.45    267      0.53    319      
  Combined age group of children, adolescents, adults                         Sikirica (2013)[@b53-ndt-10-1543]   NA           NA              NA       NA      NA       NA     NA       NA      NA       NA      NA       NA
  Lawson (2012)[@b30-ndt-10-1543]                                             0.49                                15,055       NA              NA       0.50    13,570   0.41   1,485    0.49    10,707   0.49    4,348    
  Pooled                                                                      0.49                                15,055       NA              NA       0.50    13,570   0.41   1,485    0.49    10,707   0.49    4,348    

**Note:**

For 12-month studies, the MPR was defined as the ratio of number of days for which the medication was supplied to the total number of days persistent during a 12-month follow-up period.

**Abbreviations:** MPR, medication possession ratio; LA, long acting; SA, short acting; MPH, methylphenidate; AMPH, amphetamine; NA, not applicable.

###### 

Most frequently reported reasons for treatment discontinuation in original studies

  All original studies (41 studies)                     Children and adolescents (31 studies)   Adults (five studies)   Children, adolescents, young adults (five studies)                                                                                                                                       
  ----------------------------------------------------- --------------------------------------- ----------------------- ----------------------------------------------------- ---- ---- ----------------------------------------------------- --- ---- ----------------------------------------------------- --- -----
  Adverse effects                                       30                                      73                      Ineffectiveness/suboptimal response                   21   68   Ineffectiveness/suboptimal response                   4   80   Adverse effects                                       5   100
  Ineffectiveness/suboptimal response                   27                                      66                      Adverse effects                                       21   68   Adverse effects                                       4   80   Ineffectiveness/suboptimal response                   2   40
  Poor adherence                                        8                                       20                      Poor adherence                                        7    23   Patient decision                                      2   40   Dislike of medication                                 1   20
  Parent/caregiver decision                             7                                       17                      Parent/caregiver decision                             6    19   Symptom relief                                        2   40   Lack of education                                     1   20
  Symptom relief                                        7                                       17                      Symptom relief                                        5    16   Misuse of medication                                  1   20   Parent/caregiver decision                             1   20
  Patient attitude                                      3                                       7                       Patient attitude                                      3    10   Patient attitude                                      0   0    Poor adherence                                        1   20
  Dislike of medication                                 3                                       7                       Dosing inconvenience                                  3    10   Difficulties in swallowing                            0   0    Social stigma                                         1   20
  Dosing inconvenience                                  3                                       7                       Dislike of medication                                 2    6    Dislike of medication                                 0   0    Symptom relief                                        1   20
  Patient decision                                      3                                       7                       Dosing inconvenience/social stigma                    2    6    Dosing inconvenience                                  0   0    Patient attitude                                      0   0
  Dosing inconvenience/social stigma                    2                                       5                       Health care provider decision                         2    6    Dosing inconvenience/social stigma                    0   0    Difficulties in swallowing                            0   0
  Health care provider decision                         2                                       5                       Patient decision                                      2    6    Drug holiday                                          0   0    Dosing inconvenience                                  0   0
  Social stigma                                         2                                       5                       Difficulties in swallowing                            1    3    Forgetting                                            0   0    Dosing inconvenience/social stigma                    0   0
  Difficulties in swallowing                            1                                       2                       Drug holiday                                          1    3    Health care provider decision                         0   0    Drug holiday                                          0   0
  Drug holiday                                          1                                       2                       Forgetting                                            1    3    Ineffectiveness/suboptimal response/adverse effects   0   0    Forgetting                                            0   0
  Forgetting                                            1                                       2                       Ineffectiveness/suboptimal response/adverse effects   1    3    Lack of access to medication                          0   0    Health care provider decision                         0   0
  Ineffectiveness/suboptimal response/adverse effects   1                                       2                       Lack of access to medication                          1    3    Lack of education                                     0   0    Ineffectiveness/suboptimal response/adverse effects   0   0
  Lack of access to medication                          1                                       2                       Misdiagnosed                                          1    3    Misdiagnosed                                          0   0    Lack of access to medication                          0   0
  Lack of education                                     1                                       2                       Parent education                                      1    3    Parent education                                      0   0    Misdiagnosed                                          0   0
  Misdiagnosed                                          1                                       2                       Parent/health care provider decision                  1    3    Parent/caregiver decision                             0   0    Misuse of medication                                  0   0
  Misuse of medication                                  1                                       2                       Safety concern                                        1    3    Parent/health care provider decision                  0   0    Parent education                                      0   0
  Parent education                                      1                                       2                       School factor                                         1    3    Poor adherence                                        0   0    Parent/health care provider decision                  0   0
  Parent/health care provider decision                  1                                       2                       Social stigma                                         1    3    Safety concern                                        0   0    Patient decision                                      0   0
  Safety concern                                        1                                       2                       Lack of education                                     0    0    School factor                                         0   0    Safety concern                                        0   0
  School factor                                         1                                       2                       Misuse of medication                                  0    0    Social stigma                                         0   0    School factor                                         0   0

**Notes:**

Number of studies reported specified reason for discontinuation.

Frequency of reporting specified reason for discontinuation, estimated as number of studies reporting specific reason for discontinuation divided by total number of studies in specified group.

###### 

Most frequently reported reasons for treatment discontinuation in expert opinions

  All studies with expert opinions (36 studies)   Children and adolescents (24 studies)   Adults (one study)   Children, adolescents, adults (eleven studies)                                                                                                       
  ----------------------------------------------- --------------------------------------- -------------------- ------------------------------------------------ ---- ---- ------------------------------------- --- ----- ------------------------------------- --- ----
  Adverse effects                                 24                                      67                   Adverse effects                                  15   63   Dosing inconvenience                  1   100   Adverse effects                       8   73
  Dosing inconvenience                            14                                      39                   Dosing inconvenience                             10   42   Adverse effects                       1   100   Dosing inconvenience                  3   27
  Social stigma                                   10                                      28                   Patient attitude                                 8    33   Social stigma                         1   100   Forgetting                            3   27
  Patient attitude                                9                                       25                   Social stigma                                    8    33   Patient attitude                      0   0     Ineffectiveness/suboptimal response   3   27
  Ineffectiveness/suboptimal response             7                                       19                   Patient--physician communication                 5    21   Clinician's disparity                 0   0     Patient attitude                      2   18
  Patient--physician communication                5                                       14                   Disorder-related factor                          4    17   Patient--physician communication      0   0     Difficulties in swallowing            1   9
  Disorder-related factor                         4                                       11                   Inadequate monitoring                            4    17   Comorbidity                           0   0     Education                             1   9
  Forgetting                                      4                                       11                   Ineffectiveness/suboptimal response              4    17   Difficulties in swallowing            0   0     Social stigma                         1   9
  Inadequate monitoring                           4                                       11                   Comorbidity                                      2    8    Disorder-related factor               0   0     Clinician's disparity                 0   0
  Difficulties in swallowing                      3                                       8                    Difficulties in swallowing                       2    8    Drug holiday                          0   0     Patient--physician communication      0   0
  Education                                       3                                       8                    Education                                        2    8    Education                             0   0     Comorbidity                           0   0
  Comorbidity                                     2                                       6                    Lack of access to medication                     2    8    Forgetting                            0   0     Disorder-related factor               0   0
  Lack of access to medication                    2                                       6                    Patient characteristics                          2    8    Inadequate monitoring                 0   0     Drug holiday                          0   0
  Patient characteristics                         2                                       6                    Clinician's disparity                            1    4    Ineffectiveness/suboptimal response   0   0     Inadequate monitoring                 0   0
  Clinician's disparity                           1                                       3                    Drug holiday                                     1    4    Lack of access to medication          0   0     Lack of access to medication          0   0
  Drug holiday                                    1                                       3                    Forgetting                                       1    4    Logistic difficulties                 0   0     Logistic difficulties                 0   0
  Logistic difficulties                           1                                       3                    Logistic difficulties                            1    4    Patient characteristics               0   0     Patient characteristics               0   0
  Poor adherence                                  1                                       3                    Poor adherence                                   1    4    Poor adherence                        0   0     Poor adherence                        0   0
  Self-esteem                                     1                                       3                    Self-esteem                                      1    4    Self-esteem                           0   0     Self-esteem                           0   0
  Symptom relief                                  1                                       3                    Symptom relief                                   1    4    Symptom relief                        0   0     Symptom relief                        0   0

**Notes:**

Number of studies reported specified reason for discontinuation.

Frequency of reporting specified reason for discontinuation, estimated as number of studies reporting specific reason for discontinuation divided by total number of studies in specified group.
